Coastlands Capital LP, holding a 10% ownership interest in ADIAL PHARMACEUTICALS, INC. (NASDAQ:ADIL), has executed a series of transactions to acquire additional shares of the pharmaceutical company's common stock. The investments, totaling $32,637, were completed over a two-day window between July 9 and July 10, 2026. During this period, the acquisition price per share fluctuated between $2.70 and $2.79.
On July 9, the entity purchased 10,053 shares at a price of $2.79 per share. The following day, July 10, an additional 1,700 shares were acquired at $2.70 each. These recent purchases bring Coastlands Capital LP's total indirect holding to 385,075 shares of Adial Pharmaceuticals common stock. The ownership structure is indirect, with Coastlands Capital LP acting as the investment adviser for Coastlands Capital Partners LP. Matthew Perry is identified as the control person for Coastlands Capital LP and its related entities involved in these transactions.
The insider buying activity occurs as ADIL trades at $2.84 per share. This price point is notably close to the stock's 52-week low of $1.31 and represents a significant decline of 71% over the past year. Despite these recent headwinds, analysis suggests the stock may be undervalued, citing the company's balance sheet strength where cash holdings exceed debt. This financial position is considered a critical advantage for small pharmaceutical firms navigating capital-intensive development cycles. While the stock has demonstrated strong returns over the last three months, analysts do not anticipate the company achieving profitability within the current year.
Concurrently, Adial Pharmaceuticals has finalized the first tranche of a private placement, closing $32 million of an initiative potentially reaching up to $64 million. This financing structure included the conversion of outstanding notes related to Adial's recent acquisition of Azora Therapeutics. The acquisition, valued at $32 million, integrates Azora's lead asset, AT177, into Adial's pipeline. AT177 is a treatment designed for ulcerative colitis. Additionally, Lucid Capital Markets has initiated coverage on Adial Pharmaceuticals with a buy rating, establishing a 12-month price target of $6 per share.
Further advancing its strategic focus, Adial has filed a new U.S. utility patent application for AD04, its investigational treatment for Alcohol Use Disorder. The company is seeking accelerated review through a prioritized examination process. Adial has also applied to the FDA's Commissioner's National Priority Voucher Pilot Program for its AD04 product, aiming to expedite the regulatory review process. These developments underscore the company's active efforts to expand its therapeutic offerings and secure necessary financial backing to support its pipeline.